The unprecedented nature of the Food and Drug Administration’s approval of Alzheimer’s drug Aduhelm has led to more negative publicity than perhaps any other new medication, at least in recent years. Wayne Pines, former FDA official and now president of healthcare at APCO, joins Marc Iskowitz to discuss the implications for the agency’s role in advising pharma companies and other ripple effects involving communication.